LT2956471T - Il-1beta inhibitoriaus kompozicija ir jos naudojimas - Google Patents

Il-1beta inhibitoriaus kompozicija ir jos naudojimas

Info

Publication number
LT2956471T
LT2956471T LTEPPCT/US2013/026349T LTUS2013026349T LT2956471T LT 2956471 T LT2956471 T LT 2956471T LT US2013026349 T LTUS2013026349 T LT US2013026349T LT 2956471 T LT2956471 T LT 2956471T
Authority
LT
Lithuania
Prior art keywords
inhibitor composition
1beta
1beta inhibitor
composition
inhibitor
Prior art date
Application number
LTEPPCT/US2013/026349T
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Alexey REPIK
Tao Xu
Vasily IGNATIEV
Mikhail Samsonov
Original Assignee
R-Pharm International, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51354448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2956471(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R-Pharm International, Llc filed Critical R-Pharm International, Llc
Publication of LT2956471T publication Critical patent/LT2956471T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
LTEPPCT/US2013/026349T 2013-02-15 2013-02-15 Il-1beta inhibitoriaus kompozicija ir jos naudojimas LT2956471T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/026349 WO2014126582A1 (en) 2013-02-15 2013-02-15 IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Publications (1)

Publication Number Publication Date
LT2956471T true LT2956471T (lt) 2024-06-10

Family

ID=51354448

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2013/026349T LT2956471T (lt) 2013-02-15 2013-02-15 Il-1beta inhibitoriaus kompozicija ir jos naudojimas

Country Status (24)

Country Link
EP (2) EP4050019A1 (lt)
JP (1) JP6225197B2 (lt)
KR (1) KR101989551B1 (lt)
CN (1) CN105431448B (lt)
AU (1) AU2013378122B2 (lt)
BR (1) BR112015019729B1 (lt)
DK (1) DK2956471T3 (lt)
EA (1) EA033269B1 (lt)
ES (1) ES2990881T3 (lt)
FI (1) FI2956471T3 (lt)
HR (1) HRP20240641T1 (lt)
HU (1) HUE067221T2 (lt)
IL (1) IL240553B (lt)
LT (1) LT2956471T (lt)
MX (1) MX390047B (lt)
NZ (1) NZ710900A (lt)
PH (1) PH12015501796B1 (lt)
PL (1) PL2956471T3 (lt)
PT (1) PT2956471T (lt)
RS (1) RS65559B1 (lt)
SG (1) SG11201506389YA (lt)
SI (1) SI2956471T1 (lt)
SM (1) SMT202400191T1 (lt)
WO (1) WO2014126582A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6225197B2 (ja) 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ ＩＬ−１β阻害剤組成物およびその使用
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
US11845806B2 (en) 2017-06-14 2023-12-19 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
WO2019067639A1 (en) 2017-09-26 2019-04-04 Regeneron Pharmaceuticals, Inc. TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN
MX2022014410A (es) * 2020-05-22 2022-12-06 R Pharm Overseas Inc INHIBIDOR DE IL-1ß DERIVADO DE IL1-R1 Y USO DEL MISMO.
KR20220014531A (ko) * 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途
CN116286844A (zh) * 2023-02-13 2023-06-23 浙江大学 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP2163562B1 (en) * 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
SI2235064T1 (sl) * 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
JP6225197B2 (ja) 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ ＩＬ−１β阻害剤組成物およびその使用

Also Published As

Publication number Publication date
CN105431448A (zh) 2016-03-23
EA201500842A1 (ru) 2016-02-29
WO2014126582A1 (en) 2014-08-21
SG11201506389YA (en) 2015-09-29
EP2956471A4 (en) 2019-11-13
HK1219281A1 (en) 2017-03-31
PT2956471T (pt) 2024-05-27
CN105431448B (zh) 2019-08-27
FI2956471T3 (fi) 2024-05-13
BR112015019729B1 (pt) 2023-01-24
HRP20240641T1 (hr) 2025-06-20
IL240553A0 (en) 2015-10-29
SI2956471T1 (sl) 2024-06-28
MX390047B (es) 2025-03-20
RS65559B1 (sr) 2024-06-28
KR101989551B1 (ko) 2019-09-30
SMT202400191T1 (it) 2024-07-09
AU2013378122A1 (en) 2015-08-27
PL2956471T3 (pl) 2024-06-24
NZ710900A (en) 2019-09-27
ES2990881T3 (es) 2024-12-02
AU2013378122B2 (en) 2019-05-02
JP6225197B2 (ja) 2017-11-01
PH12015501796A1 (en) 2015-11-09
IL240553B (en) 2021-02-28
EA033269B1 (ru) 2019-09-30
JP2016513106A (ja) 2016-05-12
EP2956471A1 (en) 2015-12-23
DK2956471T3 (da) 2024-05-21
PH12015501796B1 (en) 2015-11-09
BR112015019729A2 (pt) 2017-07-18
EP4050019A1 (en) 2022-08-31
HUE067221T2 (hu) 2024-10-28
MX2015010438A (es) 2016-05-05
EP2956471B1 (en) 2024-04-10
KR20160048028A (ko) 2016-05-03

Similar Documents

Publication Publication Date Title
GB201317286D0 (en) Composition and Use
PL3091008T3 (pl) Inhibitor kinazy i jego zastosowanie
GB201608553D0 (en) Strigolactone formulations and uses thereof
SI3013769T1 (sl) Ognjevarna formulacija in njena uporaba
PL3077467T3 (pl) Kompozycja suszki i jej zastosowanie
GB201321693D0 (en) Composition and uses thereof
GB201305277D0 (en) Novel combination and use
SG11201508167PA (en) Therapeutic compositions and uses thereof
SI2956471T1 (sl) Sestava za zaviralca il-1beta in njegova uporaba
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
GB2519982B (en) Fungicidal composition and the use thereof
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
SG11201510150VA (en) Immunotherapy composition and use thereof
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
PL2910131T3 (pl) Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie
GB2516838B (en) Fungicidal compositions and their use
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201322892D0 (en) Surface and composition
GB201301979D0 (en) New composition and use thereof
GB201318151D0 (en) Composition and device
FR3007291B1 (fr) Composition cicatrisante et utlisation
GB201305297D0 (en) Novel agents and uses thereof
GB2532383B (en) Set-delayed cement compositions comprising pumice and associated methods